A phase III RCT (PRONOUNCE; ClinicalTrials.gov identifier: NCT02663908) is recruiting to compare the risk of fatal or nonfatal CVD in 900 men with PCa receiving GnRH agonist or antagonist as primary treatment.15 This evidence concerns the gene GNRH1 and posterior cortical atrophy.